QLi5 Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $6.2M

  • Investors
  • 8

QLi5 Therapeutics General Information

Description

Operator of a payload platform technology intended to scale to various indications. The company specializes in treating cancers and inflammatory and autoimmune disorders, enabling medical professionals to expand the treatment area for diseases.

Contact Information

Website
qli5tx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Otto-Hahn-Straße 15
  • 44227 Dortmund
  • Germany
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • Otto-Hahn-Straße 15
  • 44227 Dortmund
  • Germany

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

QLi5 Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 27-Jan-2026 $6.2M Completed Generating Revenue
3. Early Stage VC (Series A) 07-Sep-2022 Completed Generating Revenue
2. Early Stage VC (Series A1) 14-Dec-2021 $5.65M $5.65M Completed Generating Revenue
1. Joint Venture 16-Jan-2020 Completed Generating Revenue
To view QLi5 Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

QLi5 Therapeutics Patents

QLi5 Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4155296-A1 Macrocyclic compounds as proteasome subunit beta type-5 inhibitors Inactive 24-Sep-2021
WO-2023046939-A1 Macrocyclic compounds as proteasome subunit beta type-5 inhibitors Inactive 24-Sep-2021

QLi5 Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel (individual) Minority
Atinum Investment Venture Capital Minority
DAOL Investment PE/Buyout Minority
Khanu Management Venture Capital Minority
SV Investment Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

QLi5 Therapeutics FAQs

  • When was QLi5 Therapeutics founded?

    QLi5 Therapeutics was founded in 2019.

  • Where is QLi5 Therapeutics headquartered?

    QLi5 Therapeutics is headquartered in Dortmund, Germany.

  • What industry is QLi5 Therapeutics in?

    QLi5 Therapeutics’s primary industry is Drug Discovery.

  • Is QLi5 Therapeutics a private or public company?

    QLi5 Therapeutics is a Private company.

  • What is QLi5 Therapeutics’s current revenue?

    The current revenue for QLi5 Therapeutics is .

  • How much funding has QLi5 Therapeutics raised over time?

    QLi5 Therapeutics has raised $21.9M.

  • Who are QLi5 Therapeutics’s investors?

    , Atinum Investment, DAOL Investment, Khanu Management, and SV Investment are 5 of 8 investors who have invested in QLi5 Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process